Migraine Management

Contraceptive Use and Migraine

• The American Heart Association/American Stroke Association recommends avoiding oral contraceptive agents with exogenous estrogen in women with migraine with aura, as they are contraindicated due to increased stroke risk 1
• The American College of Obstetricians and Gynecologists (ACOG) recommends progestin-only contraceptives, such as Levonorgestrel IUD (Mirena), as a preferred option for menstrual migraine prevention, with >99% effectiveness 2, 3
• Low-dose combined hormonal contraceptives (≤35 μg ethinyl estradiol) are recommended as first-line options for women with migraine without aura, if no other contraindications exist, as suggested by the American College of Obstetricians and Gynecologists 3
• The following contraceptive methods are available with their respective effectiveness and duration:

2, 3

Migraine Prevention and Treatment

• Naproxen or naproxen sodium has shown modest but statistically significant effects in preventing menstrual migraine when started 1-2 days before expected menses 2
• Frovatriptan appears to be the triptan of choice for mini-prophylaxis based on overall efficacy, with other effective options including sumatriptan, zolmitriptan, and naratriptan 2
• Transdermal estrogen therapy can be highly effective in preventing menstrual migraine when started just before menstruation, providing sustained low-level estrogen to prevent the sharp decline that triggers migraines 2
• Beta-blockers, such as propranolol 120-240 mg daily, have consistent evidence for efficacy in preventing menstrual migraine 2
• Magnesium, Vitamin B2 (Riboflavin), and Feverfew have shown benefits over placebo in multiple studies, with significant reduction in pain intensity and associated symptoms 2
• Topiramate is an appropriate second-line treatment for migraine prophylaxis, with a focus on its efficacy in chronic migraine management, as supported by strong evidence from randomized, placebo-controlled clinical trials 4, 5

Risk Assessment and Monitoring

• Women with migraine with aura have an independent increased risk of ischemic stroke (RR 2.16; 95% CI, 1.53–3.03) compared to those without aura, and this risk is compounded by additional factors such as age ≥35 years (RR 3.65; 95% CI, 2.21–6.04) or smoking (RR 9.03; 95% CI, 4.22–19.34) 6
• Oral contraceptive use in women with migraine with aura increases ischemic stroke risk by 7-fold (RR 7.02; 95% CI, 1.51–32.68) 6
• Migraine with aura is a Category 4 contraindication (unacceptable health risk) for combined hormonal contraceptives, according to the CDC Medical Eligibility Criteria 3
• Women with migraine without aura can safely use any contraceptive method, including combined hormonal contraceptives, as they do not have an increased risk of stroke compared to women with migraine with aura, as stated by the American College of Obstetricians and Gynecologists and the Centers for Disease Control and Prevention 3
• Regular follow-up (every 2-3 months initially, then every 6-12 months) is necessary to monitor changes in migraine pattern, development of aura symptoms, cardiovascular risk factors, and treatment effectiveness using headache calendars, as suggested by the American College of Neurology 7

Lifestyle Modifications

• The patient should be strongly advised to quit smoking to reduce overall cardiovascular risk, as smoking compounds the risk of stroke in women with migraine with aura 3
• Blood pressure should be monitored at baseline and during follow-up visits for women with migraine without aura using combined hormonal contraceptives, as recommended by the American Academy of Pediatrics 8
• Women with migraine without aura should be monitored for development of aura symptoms, which would require discontinuation of combined hormonal contraceptives, as advised by the American College of Obstetricians and Gynecologists 3